Press releases
- Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
- Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
- Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
- Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
Key statistics
On Friday, Everest Medicines Ltd (6HN:DEU) closed at 2.46, 103.31% above the 52 week low of 1.21 set on Jun 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.42 |
---|---|
High | 2.50 |
Low | 2.36 |
Bid | 2.42 |
Offer | 2.52 |
Previous close | 2.46 |
Average volume | 0.00 |
---|---|
Shares outstanding | 324.70m |
Free float | 194.05m |
P/E (TTM) | -- |
Market cap | 6.80bn HKD |
EPS (TTM) | -2.91 HKD |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼